Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC3R | P41968 | 3/20 | 0.65 |
| ▸ | MC4R | P32245 | 2/20 | 0.65 |
| ▸ | MC1R | Q01726 | 1/20 | 0.65 |
| ▸ | MC5R | P33032 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 3/20 | 0.34 |
| ▸ | PLG | P00747 | 2/20 | 0.34 |
| ▸ | PLAT | P00750 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26256491 | 0.95 | MC4R (0.66) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL21376777 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL22628677 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5R | |
| SCHEMBL15958510 | 0.95 | MC3R (0.59) | MC3RMC4RMC1RMC5RMAOA | |
| SCHEMBL24603690 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5R | |
| SCHEMBL24603581 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5R | |
| SCHEMBL21376779 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL22629738 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5R | |
| SCHEMBL21376480 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5RF2 | |
| SCHEMBL21376772 | 0.95 | MC4R (0.59) | MC3RMC4RMC1RMC5RF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10815275-B2 | Antimicrobial peptoids with improved selectivity and use thereof | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2020-10-27 | — | — | US | disclosed |
| US-20190284238-A1 | ANTIMICROBIAL PEPTOIDS WITH IMPROVED SELECTIVITY AND USE THEREOF | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10815275-B2 | Antimicrobial peptoids with improved selectivity and use thereof | VIP, NOD2, NGLY1 | MC3R 1916/4885MC4R 1231/4885MC1R 2893/4885 |
| US-20190284238-A1 | ANTIMICROBIAL PEPTOIDS WITH IMPROVED SELECTIVITY AND USE THEREOF | VIP, NOD2, FPR3 | MC3R 1749/4885MC4R 1357/4885MC1R 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.